Ontology highlight
ABSTRACT:
SUBMITTER: Cordes F
PROVIDER: S-EPMC7403801 | biostudies-literature | 2020 Jul
REPOSITORIES: biostudies-literature
Cordes Friederike F Foell Dirk D Ding John Nik JN Varga Georg G Bettenworth Dominik D
World journal of gastroenterology 20200701 28
In 2018, the pan-Janus kinase (JAK) inhibitor tofacitinib was launched for the treatment of ulcerative colitis (UC). Although tofacitinib has proven efficacious in patients with active UC, it failed in patients with Crohn's disease (CD). This finding strongly hints at a different contribution of JAK signaling in both entities. Here, we review the current knowledge on the interplay between the JAK/signal transducer and activator of transcription (STAT) pathway and inflammatory bowel diseases (IBD ...[more]